158 related articles for article (PubMed ID: 33605612)
1. Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients.
Kaewdech A; Sripongpun P; Cheewasereechon N; Jandee S; Chamroonkul N; Piratvisuth T
Clin Transl Gastroenterol; 2021 Feb; 12(2):e00310. PubMed ID: 33605612
[TBL] [Abstract][Full Text] [Related]
2. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study.
Wang Q; Xia D; Bai W; Wang E; Sun J; Huang M; Mu W; Yin G; Li H; Zhao H; Li J; Zhang C; Zhu X; Wu J; Li J; Gong W; Li Z; Lin Z; Pan X; Shi H; Shao G; Liu J; Yang S; Zheng Y; Xu J; Song J; Wang W; Wang Z; Zhang Y; Ding R; Zhang H; Yu H; Zheng L; Gu W; You N; Wang G; Zhang S; Feng L; Liu L; Zhang P; Li X; Chen J; Xu T; Zhou W; Zeng H; Zhang Y; Huang W; Jiang W; Zhang W; Shao W; Li L; Niu J; Yuan J; Li X; Lv Y; Li K; Yin Z; Xia J; Fan D; Han G;
J Hepatol; 2019 May; 70(5):893-903. PubMed ID: 30660709
[TBL] [Abstract][Full Text] [Related]
3. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
4. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
5. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
6. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
7. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
8. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
9. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
10. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score.
Park Y; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Park YE; Park JH; Lee YI; Yun HR; Han KH
Liver Int; 2016 Jan; 36(1):100-7. PubMed ID: 26013186
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
12. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
13. Postsurgical treatment with adjuvant transarterial chemoembolization in patients with hepatitis B-related hepatocellular carcinoma: A strobe-compliant article.
Hu H; Liu R; Long XR; Han XK; Fan J; Yan ZP; Wang JH
Medicine (Baltimore); 2016 Dec; 95(52):e5517. PubMed ID: 28033246
[TBL] [Abstract][Full Text] [Related]
14. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
15. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
17. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model.
Kim BK; Shim JH; Kim SU; Park JY; Kim DY; Ahn SH; Kim KM; Lim YS; Han KH; Lee HC
Liver Int; 2016 Jan; 36(1):92-9. PubMed ID: 25950442
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
[TBL] [Abstract][Full Text] [Related]
19. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
20. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]